Sen. Rand Paul

Maddy summaryThis bill amends the Federal Food, Drug, and Cosmetic Act to clarify the regulation of hemp-derived products. It removes hemp, hemp-derived cannabidiol (CBD), and related substances from the definition of "dietary supplements," excluding them from current supplement regulations. The bill also defines "hemp" per the Agricultural Marketing Act and grants the Secretary of Health and Human Services authority to establish labeling requirements and enforce rules for products containing these substances. This directly affects businesses selling hemp-based supplements and food products, as well as consumers purchasing them, by changing how these items are regulated under federal food safety laws.

Maddy summaryThis bill, the Free Speech Protection Act, prohibits federal employees from directing or pressuring social media platforms to censor protected speech or label content as misinformation. It bans government requests for user data related to specific topics and requires agencies to report all communications with platforms about content moderation. Violations would result in penalties including fines, job loss, and bans from government contracts. The bill also terminates the Disinformation Governance Board and prohibits government grants related to labeling content as misinformation. Affected individuals can sue government agencies and employees for violations.

Maddy summaryThe WATCH Act requires foreign laboratories receiving U.S. federal funds for animal research to undergo quarterly inspections to ensure compliance with U.S. animal welfare standards. It directly affects overseas labs conducting NIH-funded studies involving animals, mandating regular checks of their animal care committees, treatment reviews, and record-keeping. Labs must maintain certification of compliance, with public access to these certificates, and face potential suspension of funding if they fail to correct violations after a warning. The bill establishes a process for U.S. authorities to coordinate inspections with foreign governments while upholding U.S. research standards.

Maddy summaryThe Medicare Audiology Access Improvement Act of 2023 would expand Medicare coverage to include audiology services provided directly by qualified audiologists without requiring a physician referral, supervision, or that the patient be under a physician's care. Starting January 1, 2025, Medicare would cover hearing and balance assessments and treatments that audiologists are legally permitted to perform under state law, with payment set at 80% of the cost. This change would improve access to hearing care for Medicare beneficiaries and allow audiologists to practice more independently under Medicare. The bill does not alter the existing scope of covered services beyond what was available as of December 31, 2024.

Maddy summaryThis bill changes how biosimilar drugs are approved by automatically considering them interchangeable with brand-name drugs, removing a previous requirement for separate approval. It requires the FDA to brief congressional health committees before demanding certain safety studies on switching between biosimilars and reference drugs. The law affects drug manufacturers seeking FDA approval for biosimilars and the FDA itself. These changes apply only to new applications approved after the bill's enactment.

Maddy summaryThe Federal Prisons Accountability Act of 2023 would require the President to appoint the Director of the Bureau of Prisons with the advice and consent of the Senate, replacing the current system where the Director is appointed by the Attorney General. It also establishes a 10-year term for the Director, with the current Director permitted to continue serving until three months after the bill’s enactment. This change directly affects the leadership of the federal prison system, which manages 122 facilities and oversees over 159,000 inmates and 34,000 employees. The bill aligns the appointment process for the Bureau of Prisons Director with other senior Justice Department positions that require Senate confirmation.

Maddy summarySJRES 11 is a joint resolution seeking to cancel an Environmental Protection Agency (EPA) rule that set new emissions standards for heavy-duty vehicles, including trucks and buses. The rule, published in the Federal Register on January 24, 2023, would have required manufacturers to meet specific pollution control measures for new vehicles. This resolution uses a congressional disapproval process under the Congressional Review Act to nullify the EPA rule, meaning it would have no legal effect if enacted. If passed, the EPA's emissions standards for heavy-duty vehicles would be voided, removing requirements for manufacturers to comply with those specific pollution controls.

Maddy summaryThis non-binding Senate resolution states that military action taken under NATO's mutual defense clause (Article 5) does not override Congress's constitutional duty to declare war before U.S. forces engage in hostilities. It clarifies that the President cannot use NATO obligations as justification for military action without prior Congressional authorization. The resolution directly addresses how NATO commitments interact with the Constitution's war powers requirement. As a formal Senate expression of opinion, it has no legal effect but aims to reinforce Congress's role in military decisions.

Ensuring Access to Lower-Cost Medicines for Seniors Act This bill requires prescription drug plans under the Medicare prescription drug benefit to include generic drugs and biosimilars on their formularies. Specifically, the bill requires plans that use formularies to include generic drugs and biosimilars on the formularies and without any requirements (e.g., prior authorization requirements) that are more restrictive as compared to those for brand-name drugs and biologics. Plans that use cost-sharing tiers must also have specific tiers for generic drugs and biosimilars, in accordance with certain limitations.

Maddy summaryThis bill clarifies that human cadaveric islet transplants (cells from deceased donors used in diabetes treatment) are not classified as "drugs," "biological products," or "HCT/Ps" under existing federal law. It amends the Public Health Service Act to explicitly include "human cadaveric islets" in regulatory references, ensuring these transplants are not subject to the same oversight as pharmaceuticals or other biological products. The bill requires the Health Secretary to update relevant regulations within one year of enactment and report progress to Congress within six months. This change directly affects how the FDA and other agencies regulate islet transplants, streamlining their approval process without altering medical practice.